MissionIR would like to highlight CytRx Corp. (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology. The company’s pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib.
In the company’s news,
Seeking Alpha yesterday published the following article featuring CytRx: http://seekingalpha.com/article/1700372-cytrx-corporation-remains-an-undiscovered-opportunity-inthe-cancer-space?source=yahoo#comments_header
Released On: 4/8/2016
Views: 3804
Released On: 4/7/2016
Views: 4550
Released On: 3/31/2016
Views: 3519
Released On: 3/24/2016
Views: 2885
Released On: 3/17/2016
Views: 2439
Released On: 3/11/2016
Views: 2259
Released On: 3/4/2016
Views: 2579
Released On: 3/3/2016
Views: 2272
Released On: 2/23/2016
Views: 3626
Released On: 2/12/2016
Views: 2608
Released On: 2/10/2016
Views: 2326
Released On: 2/9/2016
Views: 2482
Released On: 1/20/2016
Views: 4269
Released On: 1/14/2016
Views: 4731
Released On: 1/5/2016
Views: 2978
Released On: 12/18/2015
Views: 9286
Released On: 12/9/2015
Views: 2733
Released On: 12/3/2015
Views: 3172